Long lasting octreotide LAR therapy in non functioning pancreatic neuroendocrine carcinoma

• Main Authors: Ivan Lolli, Antonio Logroscino, Simona Vallarelli, Maria A. Monteduro, Antonella Gentile, Giuseppe Troccoli
• Format: Article
• Language: English
• Published: SEEd 2015-10-01
• Series: Clinical Management Issues
• Subjects: Non functioning metastatic endocrine tumour; Histological test; Somatostatin analogues
• Online Access: https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1067

Non functioning endocrine pancreatic tumors (NF-PETs) have absent or low hormone secretion without symptoms and constitue ~60% of PETs. At diagnosis more than 50% of patients have liver metastases and almost 40% are not candidates for radical surgery because of either locally advanced disease or unresectable metastases. We described the case of a 47-year-old woman with a pancreatic carcinoma with secondarism in the liver not suitable for radical surgery. Histological test of liver metastases showed positivity for endocrine well-differentiated non functioning carcinoma expressing receptors for somatostatin with very low proliferation index (Ki67 < 2%). After this diagnosis she started a specific treatment with octreotide analogues which achieved durable stabilization of the disease.